Connect with us

Biotechnology

Zota Health Care Limited Q4fy26: Revenue Up 83.86% Yoy, Adds 997 Stores Nationwide

Zota Health Care Limited (ZOTA) reports strong FY26 results with revenue up 83.86% YoY, EBITDA at ₹2,597.73 lakhs, and expansion to 2,579 stores.

Reena Bhati - Tradealone

Published

on

Zota Health Care Limited ZOTA Q4fy26 Results: Revenue Up 83.86% Yoy

Zota Health Care Limited (ZOTA) announced its financial results for the fourth quarter and full year ended 31st March 2026, showcasing robust growth and strategic expansion. The company reported consolidated revenues of ₹53,865.75 lakhs, marking a significant year-over-year (YoY) growth of 83.86% compared to ₹29,297.48 lakhs in FY25. The consolidated gross profit stood at ₹32,468.90 lakhs, reflecting a strong increase of 108.57% YoY, driven by improved scale and operational efficiency.

Key Financial Highlights

FY26 Consolidated Revenue: ₹53,865.75 lakhs, up 83.86% YoY.

FY26 Consolidated Gross Profit: ₹32,468.90 lakhs, up 108.57% YoY.

FY26 Consolidated EBITDA: ₹2,597.73 lakhs.

Operational Expansion

Zota Health Care Limited significantly expanded its Davaindia network, adding 997 new stores during FY26, bringing the total to 2,579 stores nationwide. This marks the highest store addition in the pharma retail segment in a single financial year. The company also launched ‘All Day Stores,’ offering a wide portfolio of private label products across various categories.

Strategic Initiatives

The company reinforced its integrated business strategy by increasing its stake in Everyday Herbal Beauty Care Limited (EHBCL) to 87.78% through a rights issue, investing ₹19.47 crore. Zota also appointed Mr. Akshay Kumar as the brand ambassador for its ‘UGO Generic’ platform, aimed at delivering high-quality, affordable medicines across India.

Commenting on the FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited, said, ‘FY26 has been a defining year for Zota Health Care Limited, marked by strong execution and accelerated expansion across our Davaindia network. We have scaled our presence to 2,579 stores, alongside a significant increase in customer footfalls and GMV, reflecting growing consumer trust and deeper penetration of our affordable healthcare model.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zota Health Care LImited

Zota Health Care LImited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ZOTA
Healthcare › Biotechnology
CONSOLIDATING DOWN
40
Fundamental
70
Technical
55
Overall

1W -0.7%
1M -5.29%
3M +15.89%
Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Zota falls 9.8% over three months and has not found a floor yet. Margins of 15.4% are above average but show signs of plateauing — watch for further pressure. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 34% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 30.7% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Zota Health Care LImited.

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
56
Technical
55
Overall

1W +0.1%
1M +7.18%
3M -11.55%
P/E: 122.3 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Biotechnology

Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy

Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.

Deputy Editor, Equities for tradealone

Published

on

Dishman Carbogen Amcis Limited DCAL Q2fy27 Results

Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.

Key Financial Highlights

The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.

Segment Performance

The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.

However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.

As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

DCAL
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
34
Technical
43
Overall

1W -33.17%
1M -20.73%
3M -34.27%
P/E: 112.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.

Continue Reading

BIOCON

Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection

Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.

kuldeep yadav tradealone

Published

on

Biocon Limited Biocon FDA Approval Pebrilzo

Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.

Expanding Access to Affordable Biologics

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”

Strengthening Oncology Portfolio

Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
CONSOLIDATING DOWN
52
Fundamental
56
Technical
55
Overall

1W +0.1%
1M +7.18%
3M -11.55%
P/E: 122.3 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Trending